Hanmi Pharmaceuticals initiates a Phase 1 in German with Type 2 diabetic patients. Once weekly injection – Applied LAPSCOVERY technology
May 16, 2014 I Hanmi initiated a global Phase 1 study of a new drug (LAPS-GLP-1/GCG), which has two indications at obesity and diabetes.
Hanmi Pharmaceuticals (President & CEO Guan Sun Lee) announced that they get an approval on a phase 1 for LAPS-GLP-1/GCG in German last month.
LAPS-GLP-1/GCG is a new drug that aims for once a week injection which combines ‘GLP/Glucagon dual agonist peptide’; a combination of ‘GLP-1’ that suppresses appetite and ‘Glucagon’ which increases energy metabolism, and Hanmi’s innovative technology called ‘LAPSCOVERY’.
Hanmi targets to develop this drug for body weight loss in obese patients, blood glucose control in type 2 diabetic patients, blood glucose control and body weight loss in obese type 2 diabetic patients. Clinical study is conducted with healthy and type 2 diabetic patients.
In the first trial, Hanmi will inject LAPS-GLP-1/GCG in a single dose into 40 healthy volunteers with obesity to test the safety of the compound. In the second trial, 36 volunteers with Type 2 diabetes will be injected weekly for a month to test the efficacy of drop in blood glucose level and also the safety of the compound.
“Currently world obese population accounts for about one million, and obese diabetic patients make up 60% of entire diabetic patients.”, “This clinical trial will confirm the possibility of LAPS-GLP-1/GCG to be a next global new drug which could treat both obesity and diabetes.” said Jahoon Kang, a Clinical Director at Hanmi pharmaceutical
Meanwhile, Hanmi is combining LAPSCOVERY technology with various new products from its diabetes development pipeline. Phase 1 U.S. clinical trial for LAPS-Insulin, once-weekly dose insulin, is completed and phase 2b multinational clinical trial for LAPS-Exendin4, the product aiming for the first in market once-a-month dose exenatide, is currently on-going.
|About LAPSCOVERY| LAPSCOVERY is an innovative Long Acting Protein/Peptide Discovery Platform Technology. LAPSCOVERY prolongs the duration of drug effect of short-acting biologics, improving patients’ compliance from daily injection to weekly or monthly injection. Multi-national clinical trials led by Hanmi Pharmaceuticals are ongoing for treatment of type 2 diabetes, neutropenia and more.
SOURCE: Hanmi Pharmaceutical
Post Views: 28
Hanmi Pharmaceuticals initiates a Phase 1 in German with Type 2 diabetic patients. Once weekly injection – Applied LAPSCOVERY technology
May 16, 2014 I Hanmi initiated a global Phase 1 study of a new drug (LAPS-GLP-1/GCG), which has two indications at obesity and diabetes.
Hanmi Pharmaceuticals (President & CEO Guan Sun Lee) announced that they get an approval on a phase 1 for LAPS-GLP-1/GCG in German last month.
LAPS-GLP-1/GCG is a new drug that aims for once a week injection which combines ‘GLP/Glucagon dual agonist peptide’; a combination of ‘GLP-1’ that suppresses appetite and ‘Glucagon’ which increases energy metabolism, and Hanmi’s innovative technology called ‘LAPSCOVERY’.
Hanmi targets to develop this drug for body weight loss in obese patients, blood glucose control in type 2 diabetic patients, blood glucose control and body weight loss in obese type 2 diabetic patients. Clinical study is conducted with healthy and type 2 diabetic patients.
In the first trial, Hanmi will inject LAPS-GLP-1/GCG in a single dose into 40 healthy volunteers with obesity to test the safety of the compound. In the second trial, 36 volunteers with Type 2 diabetes will be injected weekly for a month to test the efficacy of drop in blood glucose level and also the safety of the compound.
“Currently world obese population accounts for about one million, and obese diabetic patients make up 60% of entire diabetic patients.”, “This clinical trial will confirm the possibility of LAPS-GLP-1/GCG to be a next global new drug which could treat both obesity and diabetes.” said Jahoon Kang, a Clinical Director at Hanmi pharmaceutical
Meanwhile, Hanmi is combining LAPSCOVERY technology with various new products from its diabetes development pipeline. Phase 1 U.S. clinical trial for LAPS-Insulin, once-weekly dose insulin, is completed and phase 2b multinational clinical trial for LAPS-Exendin4, the product aiming for the first in market once-a-month dose exenatide, is currently on-going.
|About LAPSCOVERY| LAPSCOVERY is an innovative Long Acting Protein/Peptide Discovery Platform Technology. LAPSCOVERY prolongs the duration of drug effect of short-acting biologics, improving patients’ compliance from daily injection to weekly or monthly injection. Multi-national clinical trials led by Hanmi Pharmaceuticals are ongoing for treatment of type 2 diabetes, neutropenia and more.
SOURCE: Hanmi Pharmaceutical
Post Views: 28
